Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

DA-020

PreclinicalSmall molecule

AApplied Biology, Inc.

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chemotherapy Induced AlopeciaRecruiting

Chemotherapy Induced AlopeciaPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Study completion

NCT07402330

Q1 2027

PreclinicalRecruiting

Chemotherapy Induced Alopecia

NCT07397325

Clinical

Trials by Indication[1]

Chemotherapy Induced Alopecia1 trial

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

Recruiting·AApplied Biology, Inc.·Preclinical·NCT07397325·60 enrolled

Unspecified1 trial

Pharmacokinetic Study of DA-020

Not yet recruiting·AApplied Biology, Inc.·Phase 1·NCT07402330·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DA-020. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-020 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-020. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Applied Biology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AApplied Biology, Inc.

Related News